Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and UseBiodexa plans to ...

A free fatty acid form of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) reduces both the size and number of polyps in patients with familial adenomatous polyposis (FAP ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Considering taking supplements to treat sinonasal polyposis? Below is a list of common natural remedies used to treat or reduce the symptoms of sinonasal polyposis. Follow the links to read common ...

Multi-target stool DNA test adherence among average-risk 45- to 49-year-old patients from 2017-2023. Refining colorectal cancer screening strategies using polygenic risk scores and classical risk ...

Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...

Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial. Phase Ib study of gevokizumab (GEVO) ...

Shares of Biodexa Pharmaceuticals skyrocketed nearly 50% on Monday, hitting their highest level since early December. The Cardiff, UK-based company's stock surge followed the U.S. FDA granting its ...